Wallingford, CT, United States of America

Mark D Wittman

This inventor holds 32 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 9 EPO patents, primarily in Kinase Inhibitors. Top assignees: Bristol-Myers Squibb Compnay, Virginia Tech Intellectual Properties Inc.. Active years: 1993-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mark D Wittman. Retrieved from https://idiyas.com/inventor/mark-d-wittman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 32 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 9 (Patent Applications = 7)

Average Co-Inventor Count = 4.4

ph-index = 8

Forward Citations = 210(Granted Patents)

Location History:

Cheshire, CT (US) (1993 - 2002)
Waliingford, CT (US) (2007)
Wallingford, CT (US) (2002 - 2018)
Hopkinton, MA (US) (2021)

Company Filing History:

32 out of 3,737

Bristol-Myers Squibb Compnay

patents

1 out of 823

Virginia Tech Intellectual Properties Inc.

patents

where one patent can have more than one assignee

Years Active: 1993-2021

Loading Chart...

Areas of Expertise:

Isofuranone Compounds

Imidazo-Pyridazine Derivatives

Casein Kinase Inhibitors

Pyrazole Substituted Imidazoles

Thiazolyl Compounds

Pyrrolotriazine Kinase Inhibitors

Tyrosine Kinase Inhibitors

Taxane Anticancer Agents

Cytotoxic Compounds

Benzimidazole Heterocycles

Amino Acid Derivatives

Hybrid Antitumor Compounds

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11166959 - Isofuranone compounds useful as HPK1 inhibitors (2021-11-09),

2. 9956220 - Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors (2018-05-01),

3. 9598423 - Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors (2017-03-21),

4. 9556179 - Substituted imidazoles as casein kinase 1 D/E inhibitors (2017-01-31),

5. 9475817 - Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors (2016-10-25),

6. 9273058 - Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors (2016-03-01),

7. 8592579 - Pyrrolotriazine kinase inhibitors (2013-11-26),

8. 8415340 - Triazine kinase inhibitors (2013-04-09),

9. 8343999 - Thiazolyl compounds useful as kinase inhibitors (2013-01-01),

10. 8263765 - Pyrrolotriazine kinase inhibitors (2012-09-11),

11. 8198438 - Pyrrolotriazine kinase inhibitors (2012-06-12),

12. 8148400 - Thiazolyl compounds useful as kinase inhibitors (2012-04-03),

13. 7879855 - Pyrrolotriazine kinase inhibitors (2011-02-01),

14. 7534792 - Pyrrolotriazine kinase inhibitors (2009-05-19),

15. 7470696 - Tyrosine kinase inhibitors (2008-12-30),

Title: **Mark D. Wittman: Innovator in Pharmaceutical Chemistry**

Introduction

Mark D. Wittman, an accomplished inventor based in Wallingford, Connecticut, has made significant contributions to the field of pharmaceutical chemistry, holding a remarkable total of 32 patents. His work primarily focuses on developing novel compounds that target critical pathways in treating various diseases, including cancer and viral infections.

Latest Patents

Among his latest innovations are two noteworthy patents. The first patent involves isofuranone compounds, which serve as hematopoietic progenitor kinase 1 (HPK1) inhibitors. The disclosed compounds, defined by specific formulas, are showcased for their potential utility in modulating or inhibiting HPK1's enzymatic activity. These compounds are particularly promising for addressing viral infections and proliferative disorders, such as cancer.

The second patent presents imidazo-pyridazine derivatives that act as inhibitors of casein kinase 1 δ/ε. These compounds are designed to inhibit protein kinase activity, positioning them as potential anticancer agents due to their therapeutic applications in oncology.

Career Highlights

Throughout his career, Mark D. Wittman has held significant positions at prominent organizations, including Bristol Myers Squibb Company and Virginia Tech Intellectual Properties, Inc. His experiences at these institutions have undoubtedly enriched his expertise and innovation capabilities in pharmaceutical research.

Collaborations

Mark has collaborated with notable coworkers such as Upender Velaparthi and John F. Kadow. Their collective efforts have contributed to driving advancements in their respective fields, advancing the understanding and treatment of various diseases through innovative research.

Conclusion

In conclusion, Mark D. Wittman's extensive portfolio of patents and his dedicated work in pharmaceutical chemistry underscore his status as a leading innovator. His research not only enhances scientific knowledge but also paves the way for developing effective treatments for health challenges, particularly in cancer and viral infections.

Profile summary based on public USPTO records.